SciSparc

Cannabinoid Pharmaceuticals for Treatment of Central Nervous System Disorders

Health Tech & Life Sciences
Public on NASDAQ on Mar 2017
Public Giv'atayim, Israel Founded 2004
Last updated 2026-06-18
Total raised
$63.8M
Last: PIPE 2026-01
Stage
Public
Founded
2004
Headcount
4
HQ
Giv'atayim, Israel
Sector
Health Tech & Life Sciences

About

SciSparc is a specialty clinical-stage pharmaceutical company focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company is currently engaged in drug development programs based on THC and/or non-psychoactive cannabidiol (CBD), including SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimers disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy.

Funding history · 9 rounds · $63.8M total

2005-12
Public Offering $10.4M
2017-03
Public Offering $12.0M
2019-04
2019-12
2020-11
Public Offering $4.2M
2021-03
2022-06
2023-10
2026-01
PIPE $9.2M

Q&A

What is SciSparc's primary focus as a pharmaceutical company?
SciSparc is a clinical-stage pharmaceutical company specializing in creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.
What drug development programs is SciSparc currently engaged in?
SciSparc is engaged in drug development programs based on THC and/or non-psychoactive cannabidiol (CBD), including SCI-110 for Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for pain; and SCI-210 for autism spectrum disorder and epilepsy.
When did SciSparc complete its most recent funding round?
SciSparc completed a PIPE funding round in January 2026, raising $9,180,000.
What was SciSparc's most recent acquisition?
SciSparc acquired Neurothera Labs in October 2025.
What was SciSparc's most recent public offering?
SciSparc had a public offering in August 2023, raising $1,300,000 on NASDAQ under the ticker SPRC.
When was SciSparc founded?
SciSparc was founded in August 2004.
What is the current status of SciSparc?
SciSparc is a public company, having gone public on NASDAQ in March 2017.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyMedical Cannabis
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 PatentsVerified

Tags

chronic-painpain-reliefcns-disordersdrug-developmentapneapharmaceuticalsautismchronic-diseasealzheimers-diseaseinfectious-diseasemental-healthcancermedical-cannabisimmunotherapyepilepsytherapeuticsdrug-delivery
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitescisparc.com/
LinkedInlinkedin.com/company/71540465
Facebookfacebook.com/SciSparc

Identifiers & details

Legal nameSciSparc
Former namesTherapix Biosciences, Nasvax
Founded2004-8
Employees (exact)4
Market cap$4.5M
Status reasonPublic on NASDAQ on Mar 2017;

Acquisitions & public offerings

AcquiredDateAmount
2025-10
2014-10
2014-08$2.3M
TypeDateExchangeTickerAmount
2023-08SPRC$1.3M
2021-12SPRC
2021-08
2020-11TRPXY$4.2M
2020-07TRPXY
2018-08
2017-03SPRC$12.0M
2005-12THXBY$10.4M